mesoblast' covid 19 forai other new good bad ugli biopharma nasdaq:meso seek alpha seek alpha sign inmarketplacesubscrib premium premium overview compar stock fund notabl call new dashboard top rate stock top dividend stock top reit top growth stock my portfolio creat portfolio manag email summari manag real time email alert author my author author email alert latest stocktalk top stock rate screener etf screener latest new latest new notabl call move top new wall street breakfast ipo new m new u. economi tech new energi new healthcar new crypto new top mover earn earn new earn calendar see all section market market outlook today’ market economi gold preciou metal commod forex real estat editor pick cryptocurr global invest center stock idea long idea ipo analysi quick pick list fund letter close end fund stock idea sector stock idea editor pick short idea dividend dividend idea dividend new reit dividend strategi dividend quick pick dividend etf real estat etf dividend editor pick fix incom retir etf etf analysi etf screener editor pick let’ talk etf etf perform sector etf perform countri etf perform market cap invest strategi invest strategi editor pick portfolio strategi financi advisor podcast latest podcast wall street breakfast cannabi invest behind idea let’ talk etf sa fa marketplac roundtabl invest edg alpha trader help support knowledg base feedback forum seek alpha mesoblast' covid 19 forai other new good bad ugli biopharma apr 8 2020 5 16 pm et about mesoblast limit meso includ blph crnx meobf avisol capit partner avisol capit partner total pharma tracker how make monei scientif predict biopharma sector summari mesoblast up ind approv target covid 19 crinet announc posit trial data bellerophon announc earn program updat mesoblast get fda go ahead covid 19 treatment applic mesoblast limit meso announc u fda ha clear it investig new drug applic treat patient suffer from acut respiratori distress syndrom ard due coronaviru infect us remestemcel l compani intend us intraven infus it allogen mesenchym stem cell msc product mesoblast report drug candid be develop treat differ inflammatori condit believ work down regul product pro inflammatori cytokin drug also believ increas product anti inflammatori cytokin mesoblast' chief medic offic dr fred grossman said fda clearanc provid pathwai unit state us remestemcel l patient covid 19 ard where prognosi veri dismal under both expand access compassion us plan random control trial compani ha evalu safeti therapeut impact remestemcel l intraven infus more than 1,100 patient variou clinic trial drug show posit result dure it phase 3 trial steroid refractori acut graft versu host diseas agvhd children potenti fatal ailment caus cytokin storm process similar covid 19 ard mesoblast report separ post hoc analysi placebo control studi patient chronic obstruct pulmonari diseas demonstr remestemcel l significantli improv respiratori function patient suffer from same elev inflammatori biomark also observ patient covid 19 ard studi involv 60 patient random observ back decis evalu potenti drug candid treat patient covid 19 ard drug candid ha alreadi been accept fda under it prioriti review pathwai applic pertain us drug manag steroid refractori acut graft versu host diseas acut gvhd drug expect launch u market 2020 treat pediatr steroid refractori acut graft versu host diseas acut gvhd subject approv mesoblast lead pharma compani involv develop allogen cellular medicin compani us it proprietari mesenchym lineag cell therapi technologi platform develop broad arrai commerci drug late stage drug candid company' proprietari manufactur process capabl produc industri scale off shelf cellular medicin medicin also cryopreserv mesoblast ha robust portfolio product protect go least 2040 major market compani also ha solid market commerci collabor place mesoblast recent report it first half end decemb 31 2019 compani show 43 percent increas it revenu touch 19.2 million figur mesoblast had report it revenu correspond time period previou year 13.5 million it loss after tax drop 32 percent 30.1 million comparison post tax loss 44.1 million first half previou fy decemb 31 2019 compani had 81.3 million cash hand while expect gener addit 62.5 million next 12 month through current financ facil strateg partnership mesoblast state expect data readout revascor treat advanc chronic heart failur phase 3 trial dure mid 2020 also plan start confirmatori trial evalu efficaci drug candid treat end stage heart failur crinet pharmaceut announc posit trial result crinet pharmaceut crnx report posit interim result from it acrobat edg phase 2 trial result demonstr acromegali patient who made switch from inject depot therapi onc daili oral paltusotin formerli crn00808 show same igf 1 level previous obtain us commerci avail depot inject somatostatin receptor ligand srl interim result were deriv from exploratori analysi first 13 patient who were enrol edg trial us octreotid lanreotid depot monotherapi call group 1 data further show 10 out 11 patient group 1 who complet paltusotin treatment maintain igf 1 level within 15 respect baselin level week 13 none patient requir rescu therapi prior inject peptid acromegali therapi after switch paltusotin 12 patient who had igf 1 level measur two week after paltusotin withdraw show mean increas igf 1 from baselin 0.74 x uln crinet pharmaceut re post recruit acrobat edg ha been complet alan krasner m.d chief medic offic crinet said patient enter studi repres approxim two third acromegali patient who treat srl monotherapi recruit acrobat edg now complet toplin data anticip fourth quarter year compani also plan take drug candid phase 3 dure first half 2021 crinet provid further updat about it differ develop program compani said current undertak first human enabl activ oral nonpeptid acth antagonist well oral nonpeptid sst5 agonist phase 1 clinic trial like begin late 2020 earli 2021 upon success complet crinet expect pk pd data from human proof concept studi readi first half 2021 compani also report expect it cash runwai extend 2022 bellerophon therapeut announc result fall short expect bellerophon therapeut blph announc it fourth quarter full year result compani report it net loss year 13.3 million 2.95 per share down from net incom 2.8 million 0.73 per share had announc previou year it research develop expens year stood 11 million comparison 20.3 million previou year company' q4 ep 0.89 fell short consensu estim 0.33 bellerophon report cash cash equival 9.9 million decemb 31 2019 while had 16.6 million end previou financi year it gener administr expens year stood 6.4 million down from 7.6 million had incur 2018 decreas mainli account lower consult expens reduct stock base compens expens compani also provid updat about it clinic program report receiv fda nod expand access treatment inopuls compani also carri out phase 2 dose escal studi ph sarc trial aim assess acut hemodynam benefit inopuls via right heart catheter compani also recent report posit top line data from phpf 002 recent complet ancillari dose escal studi assess acut hemodynam effect inopuls ph pf via right heart catheter thank read total pharma tracker we do more than follow biotech new us our iomachin our team analyst work ahead curv mean when catalyst come make break stock we'v posit ourselv success we share posit all analysi behind our member disclosur i we have posit ani stock mention plan initi ani posit within next 72 hour i wrote articl myself express my own opinion i am receiv compens other than from seek alpha i have busi relationship ani compani whose stock mention articl addit disclosur i recommend meso our subscrib when trade less than 4 i ask them exit 8 which attain premarket yesterdai follow avisol capit partner get email alert add comment disagre articl submit your own report factual error articl click here your feedback matter u seek alpha rss feed sitemap about u feedback career contact u term us privaci market data disclaim 2020 seek alpha